Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis
Cardiovascular diseases (CVDs) represent the most important epidemic of our century, with more than 37 million patients globally. Furthermore, CVDs are associated with high morbidity and mortality, and also increased hospitalization rates and poor quality of life. Out of the plethora of conditions t...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Crystals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4352/11/10/1172 |
| _version_ | 1797514934418931712 |
|---|---|
| author | Mihai Ștefan Cristian Haba Dragomir N. Șerban Lăcrămioara Șerban Ivona Maria Tudorancea Raluca Maria Haba Ovidiu Mitu Radu Iliescu Ionuț Tudorancea |
| author_facet | Mihai Ștefan Cristian Haba Dragomir N. Șerban Lăcrămioara Șerban Ivona Maria Tudorancea Raluca Maria Haba Ovidiu Mitu Radu Iliescu Ionuț Tudorancea |
| author_sort | Mihai Ștefan Cristian Haba |
| collection | DOAJ |
| description | Cardiovascular diseases (CVDs) represent the most important epidemic of our century, with more than 37 million patients globally. Furthermore, CVDs are associated with high morbidity and mortality, and also increased hospitalization rates and poor quality of life. Out of the plethora of conditions that can lead to CVDs, atherosclerosis and ischemic heart disease are responsible for more than 2/3 of the cases that end in severe heart failure and finally death. Current therapy strategies for CVDs focus mostly on symptomatic benefits and have a moderate impact on the underlying physiopathological mechanisms. Modern therapies try to approach different physiopathological pathways such as reduction of inflammation, macrophage regulation, inhibition of apoptosis, stem-cell differentiation and cellular regeneration. Recent technological advances make possible the development of several nanoparticles used not only for the diagnosis of cardiovascular diseases, but also for targeted drug delivery. Due to their high specificity, nanocarriers can deliver molecules with poor pharmacokinetics and dynamics such as: peptides, proteins, polynucleotides, genes and even stem cells. In this review we focused on the applications of nanoparticles in the diagnosis and treatment of ischemic heart failure and atherosclerosis. |
| first_indexed | 2024-03-10T06:38:35Z |
| format | Article |
| id | doaj.art-6da956b0b3de4ff4ab879d9f89439a51 |
| institution | Directory Open Access Journal |
| issn | 2073-4352 |
| language | English |
| last_indexed | 2024-03-10T06:38:35Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Crystals |
| spelling | doaj.art-6da956b0b3de4ff4ab879d9f89439a512023-11-22T17:52:45ZengMDPI AGCrystals2073-43522021-09-011110117210.3390/cryst11101172Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and AtherosclerosisMihai Ștefan Cristian Haba0Dragomir N. Șerban1Lăcrămioara Șerban2Ivona Maria Tudorancea3Raluca Maria Haba4Ovidiu Mitu5Radu Iliescu6Ionuț Tudorancea7Department of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Physiology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Physiology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaFaculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaFaculty of General Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Pharmacology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaDepartment of Physiology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iași, RomaniaCardiovascular diseases (CVDs) represent the most important epidemic of our century, with more than 37 million patients globally. Furthermore, CVDs are associated with high morbidity and mortality, and also increased hospitalization rates and poor quality of life. Out of the plethora of conditions that can lead to CVDs, atherosclerosis and ischemic heart disease are responsible for more than 2/3 of the cases that end in severe heart failure and finally death. Current therapy strategies for CVDs focus mostly on symptomatic benefits and have a moderate impact on the underlying physiopathological mechanisms. Modern therapies try to approach different physiopathological pathways such as reduction of inflammation, macrophage regulation, inhibition of apoptosis, stem-cell differentiation and cellular regeneration. Recent technological advances make possible the development of several nanoparticles used not only for the diagnosis of cardiovascular diseases, but also for targeted drug delivery. Due to their high specificity, nanocarriers can deliver molecules with poor pharmacokinetics and dynamics such as: peptides, proteins, polynucleotides, genes and even stem cells. In this review we focused on the applications of nanoparticles in the diagnosis and treatment of ischemic heart failure and atherosclerosis.https://www.mdpi.com/2073-4352/11/10/1172nanoparticlescardiovascular diseasetargeted therapyatherosclerosis |
| spellingShingle | Mihai Ștefan Cristian Haba Dragomir N. Șerban Lăcrămioara Șerban Ivona Maria Tudorancea Raluca Maria Haba Ovidiu Mitu Radu Iliescu Ionuț Tudorancea Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis Crystals nanoparticles cardiovascular disease targeted therapy atherosclerosis |
| title | Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis |
| title_full | Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis |
| title_fullStr | Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis |
| title_full_unstemmed | Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis |
| title_short | Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis |
| title_sort | nanomaterial based drug targeted therapy for cardiovascular diseases ischemic heart failure and atherosclerosis |
| topic | nanoparticles cardiovascular disease targeted therapy atherosclerosis |
| url | https://www.mdpi.com/2073-4352/11/10/1172 |
| work_keys_str_mv | AT mihaistefancristianhaba nanomaterialbaseddrugtargetedtherapyforcardiovasculardiseasesischemicheartfailureandatherosclerosis AT dragomirnserban nanomaterialbaseddrugtargetedtherapyforcardiovasculardiseasesischemicheartfailureandatherosclerosis AT lacramioaraserban nanomaterialbaseddrugtargetedtherapyforcardiovasculardiseasesischemicheartfailureandatherosclerosis AT ivonamariatudorancea nanomaterialbaseddrugtargetedtherapyforcardiovasculardiseasesischemicheartfailureandatherosclerosis AT ralucamariahaba nanomaterialbaseddrugtargetedtherapyforcardiovasculardiseasesischemicheartfailureandatherosclerosis AT ovidiumitu nanomaterialbaseddrugtargetedtherapyforcardiovasculardiseasesischemicheartfailureandatherosclerosis AT raduiliescu nanomaterialbaseddrugtargetedtherapyforcardiovasculardiseasesischemicheartfailureandatherosclerosis AT ionuttudorancea nanomaterialbaseddrugtargetedtherapyforcardiovasculardiseasesischemicheartfailureandatherosclerosis |